[go: up one dir, main page]

NO20042035L - Forbedret anvendelse av antitumorforbindelse i kreftterapi - Google Patents

Forbedret anvendelse av antitumorforbindelse i kreftterapi

Info

Publication number
NO20042035L
NO20042035L NO20042035A NO20042035A NO20042035L NO 20042035 L NO20042035 L NO 20042035L NO 20042035 A NO20042035 A NO 20042035A NO 20042035 A NO20042035 A NO 20042035A NO 20042035 L NO20042035 L NO 20042035L
Authority
NO
Norway
Prior art keywords
cancer therapy
improved use
antitumor compound
antitumor
compound
Prior art date
Application number
NO20042035A
Other languages
English (en)
Inventor
Jose Jimeno
Ana Ruiz Casado
Eric Rowinsky
Manual Hidalgo
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20042035L publication Critical patent/NO20042035L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
NO20042035A 2001-10-19 2004-05-18 Forbedret anvendelse av antitumorforbindelse i kreftterapi NO20042035L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34841401P 2001-10-19 2001-10-19
PCT/US2002/033548 WO2003039571A1 (en) 2001-10-19 2002-10-21 Improved use of antitumoral compound in cancer therapy

Publications (1)

Publication Number Publication Date
NO20042035L true NO20042035L (no) 2004-05-18

Family

ID=23367939

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042035A NO20042035L (no) 2001-10-19 2004-05-18 Forbedret anvendelse av antitumorforbindelse i kreftterapi

Country Status (15)

Country Link
US (1) US20050004018A1 (no)
EP (1) EP1435988A4 (no)
JP (1) JP2005509650A (no)
KR (1) KR20050038578A (no)
CN (1) CN1606449A (no)
AU (1) AU2002343548B2 (no)
BR (1) BR0213424A (no)
CA (1) CA2462502A1 (no)
HU (1) HUP0401903A3 (no)
IL (1) IL161430A0 (no)
MX (1) MXPA04003674A (no)
NO (1) NO20042035L (no)
PL (1) PL368458A1 (no)
RU (1) RU2306933C2 (no)
WO (1) WO2003039571A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2428160C (en) * 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7622458B2 (en) * 2003-11-13 2009-11-24 Pharma Mar, S.A.U. Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
NZ552607A (en) * 2004-07-09 2009-07-31 Pharma Mar Sa Prognostic molecular markers
US20090117176A1 (en) * 2004-10-26 2009-05-07 Pharma Mar, S.A. Sociedad Unipersonal Anticancer Treatments
NZ554761A (en) * 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2007249281A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
DK2716301T3 (en) * 2007-02-16 2017-07-31 Merrimack Pharmaceuticals Inc ANTIBODIES AGAINST ERBB3 AND APPLICATIONS THEREOF
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
PE20120015A1 (es) * 2008-08-15 2012-01-26 Merrimack Pharmaceuticals Inc Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
CA2792327C (en) 2010-03-11 2019-09-24 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
CN108295058A (zh) 2012-11-13 2018-07-20 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US7202361B2 (en) * 2000-04-12 2007-04-10 Pharmamar Antitumoral ecteinascidin derivatives
CA2428160C (en) * 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
NZ554761A (en) * 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide

Also Published As

Publication number Publication date
WO2003039571A1 (en) 2003-05-15
IL161430A0 (en) 2004-09-27
PL368458A1 (en) 2005-03-21
RU2004115110A (ru) 2005-03-10
CA2462502A1 (en) 2003-05-15
MXPA04003674A (es) 2004-07-23
RU2306933C2 (ru) 2007-09-27
HUP0401903A3 (en) 2008-07-28
EP1435988A4 (en) 2008-01-09
AU2002343548B8 (en) 2003-05-19
AU2002343548B2 (en) 2007-11-08
BR0213424A (pt) 2004-12-14
HUP0401903A2 (hu) 2005-01-28
KR20050038578A (ko) 2005-04-27
CN1606449A (zh) 2005-04-13
EP1435988A1 (en) 2004-07-14
JP2005509650A (ja) 2005-04-14
US20050004018A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
NO20042035L (no) Forbedret anvendelse av antitumorforbindelse i kreftterapi
CY2019030I2 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
IL169594A0 (en) Treatment of cancer with 2-deoxyglucose
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
AU6048201A (en) Quinazoline derivatives for the treatment of tumours
EP1392818A4 (en) FOR THE TREATMENT OF CANCER DISEASES IN HUMAN CERTAIN IMMUNE RECEPTOR
EP1482970A4 (en) ANTICANCER THERAPY
IS6891A (is) Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins
NO20034780L (no) Antiangiogenisk kombinasjonsterapi for behandling av kreft
IL159887A0 (en) Combination therapy for the treatment of cancer
AU2003212634A8 (en) Compounds useful in the treatment of cancer
HK1068551A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
NO20014228D0 (no) Radioaktiv cisplatin i behandling av cancer
AU2003231803A8 (en) Treatment of cancer with mefloquire
GB0226595D0 (en) Cancer therapy determination
GB0329416D0 (en) Treatment of cancer
EP1463511A4 (en) COMBINATORY ANTICANCER THERAPY
NO20042850L (no) Kreftbehandling
GB0129451D0 (en) Treatment of cancer
GB0125764D0 (en) Diagnosis of cervicasl cancer
AU2003217925A1 (en) Treatment of metastatic institute for cancer
GB0008161D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application